When immune checkpoint antibodies first entered the clinic a decade ago, they were hailed as a revolution. Drugs targeting PD‑1 and CTLA‑4 rewrote the rules of oncology, offering durable responses in cancers once considered untreatable. Today, the story is less about discovery and more about refinement: how to manufacture these complex molecules at scale, how to test them in ever more realistic...